COMMUNIQUÉS West-GlobeNewswire

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
29/04/2024
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting • Execution of strategic collaboration and [...]
Travere Therapeutics to Report First Quarter 2024 Financial Results
29/04/2024
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the close of the U.S. [...]
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
29/04/2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2023 Q4 AND FULL YEAR FINANCIAL RESULTS
29/04/2024
Greenville, South Carolina, April 29, 2024 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) a leading US-based franchise system providing drug testing, alcohol screening, DNA and direct to [...]
Streamline Health® Reports Fiscal Fourth Quarter and Full Year 2023 Financial Results
29/04/2024
14% growth of SaaS revenue in fiscal 2023 compared to fiscal 2022 $0.4 million of adjusted EBITDA generated in the fourth quarter of fiscal 2023 compared to ($0.2 million) during the fourth quarter of fiscal 2022; $2.4 [...]
Better Choice Company Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
29/04/2024
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE American: BTTR) (the “Company” or “Better Choice”), a pet health and wellness company, announced today that it received a notice (the “Notice [...]
OpGen Provides Update on Business Operations and Strategic Opportunities
29/04/2024
ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of [...]
Option Care Health to Participate in the BofA Securities Health Care Conference
29/04/2024
BANNOCKBURN, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, will [...]
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
29/04/2024
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, [...]
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
29/04/2024
Reported first quarter 2024 revenue from continuing operations 1 of $61.5M with 96% year-over-year growth of exome and genome test revenue Expanded first quarter 2024 adjusted gross margins 2 from continuing operations [...]
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
29/04/2024
Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class Pharmacokinetic data show no clinically significant difference in exposure between [...]
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024
29/04/2024
WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
29/04/2024
Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 // Net sales at CER of $462 million ahead of outlook for at least $455 [...]
Oculis Publishes Invitation to the Annual General Meeting
29/04/2024
ZUG, Switzerland, April 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), today published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29/04/2024
WATERTOWN, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Teknova to Report First Quarter 2024 Financial Results on May 13, 2024
29/04/2024
HOLLISTER, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
29/04/2024
SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European [...]
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
29/04/2024
WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
Pediatric Brain Tumor Foundation celebrates FDA approval of Day One Biopharmaceuticals’ OJEMDA™, new treatment for common pediatric brain tumor type
29/04/2024
Early research funding from the PLGA Foundation contributed to development of OJEMDA (tovorafenib), the first-of-its-kind treatment for pediatric low-grade glioma (pLGG), the most commonly diagnosed pediatric brain [...]

Pages